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OBJECTIVE—Alteration of placental structure may inﬂuence
fetal overgrowth and complications of maternal diabetes. We
examined the placenta in a cohort of offspring of mothers with
type 1 diabetes (OT1DM) to assess structural changes and
determine whether these were related to maternal A1C, fetal
hematocrit, fetal hormonal, or metabolic axes.
RESEARCH DESIGN AND METHODS—Placental samples
were analyzed using stereological techniques to quantify volumes
and surface areas of key placental components in 88 OT1DM and
39 control subjects, and results related to maternal A1C and
umbilical cord analytes (insulin, leptin, adiponectin, IGF-I, he-
matocrit, lipids, C-reactive protein, and interleukin-6).
RESULTS—Intervillous space volume was increased in OT1DM
(OT1DM 250  81 cm
3 vs. control 217  65 cm
3; P  0.02) with
anisomorphic growth of villi (P  0.025). The placentas showed
a trend to increased weight (OT1DM 690  19 g; control 641 
22 g; P  0.08), but villous, nonparenchymal, trophoblast, and
capillary volumes did not differ. Villous surface area, capillary
surface area, membrane thickness, and calculated morphometric
diffusing capacity were also similar in type 1 diabetic and control
subjects. A1C at 26–34 weeks associated with birth weight (r 
0.27, P  0.03), placental weight (r  0.41, P  0.0009), and
intervillous space volume (r  0.38, P  0.0024). In multivariate
analysis of cord parameters in OT1DM, fetal IGF-I emerged as a
signiﬁcant correlate of most components (intervillous space,
villous, trophoblast, and capillary volumes, all P  0.01). By
contrast, fetal insulin was only independently associated with
capillary surface area (positive, r
2  6.7%; P  0.02).
CONCLUSIONS—There are minimal placental structural differ-
ences between OT1DM and control subjects. Fetal IGF-I but not
fetal insulin emerges as a key correlate of placental substructural
volumes, thereby facilitating feedback to the placenta regarding
fetal metabolic demand. Diabetes 58:2634–2641, 2009
M
aternal diabetes is associated with adverse
consequences to mother and baby, with in-
creased risks of perinatal morbidity and mor-
tality, in particular in association with fetal
macrosomia. The Pedersen hypothesis (1) proposed that
maternal hyperglycemia drives increased transplacental
glucose transfer and thereby compensatory fetal hyperin-
sulinemia and induction of fetal growth. Although the fetal
consequences of maternal glycemia are clearly recognized,
there is still uncertainty about the role of the placenta in
determining these outcomes. Speciﬁcally, the nature and
scale of attendant structural change within the type 1
diabetic placenta remains contentious. Notably, the re-
spective contribution of placental structural differences
and how these relate to fetal hormonal axes in the
attainment of enhanced placental and fetal growth is also
unknown, even in control populations.
Classically, older histological studies of type 1 diabetic
placentas have described grossly abnormal placentas that
are enlarged, thick, and plethoric, with abnormalities of
villous maturation (2). These changes would all support
the increased incidence of placental-related complications
observed in diabetic pregnancy (3). However, other histor-
ical series have not detected signiﬁcant differences (2),
and more recent stereological studies continue to differ
with either no disparity in placental composition (4,5) or
isolated changes including increases in capillary volume
and surface area (6,7), increased villous surface area (8),
increased total diffusive conductance (9), and increased
intervillous and trophoblast volume (7,10). This lack of
consistency may reﬂect a combination of small series,
grouping of different classes of maternal diabetes, differ-
ences in glycemic control between individual patients,
recent improvements in antenatal care, and differing
methodology.
To date, studies in diabetes have also largely used fetal
macrosomia as a surrogate of maternal glycemia and
excessive transplacental glucose transfer (7,10) rather
than assessment of the fetal hormonal response including
hyperinsulinemia. Certainly, fetal hyperinsulinemia has an
independent positive association with birth weight and
placental weight in offspring of mothers with type 1
diabetes (OT1DM) (11). IGF-I and IGF-II also inﬂuence
feto-placental growth. IGF-I has strong correlations to
both birth weight and placental weight in control subjects
and OT1DM (11–13). The role of IGF-II is less clear in
human studies and is likely modiﬁed by circulating IGF-II
receptor (12). Adiponectin, although not directly associ-
ated with birth weight, does correlate with placental
weight and contributes to the matching of fetal and
placental growth in control subjects and OT1DM (11,14).
Finally, leptin also correlates with placental weight in
control subjects and OT1DM and has recently been pro-
posed as an in utero signal of nutrient availability (11,15).
Collectively, these fetal hormone axes may therefore fa-
cilitate enhanced growth of the fetus and compensatory
changes within the placenta, including structural modiﬁ-
cation, particularly in response to an excessive glucose
supply as seen in diabetic pregnancy. To address this
potential interaction of maternal environment, fetal hor-
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tas in relation to birth weight, neonatal adiposity, and fetal
hormonal indexes, in particular those of insulin and IGF-I
in OT1DM.
RESEARCH DESIGN AND METHODS
Recruitment and collection of cord blood. Recruitment, which began in
January 1999 and ended in May 2001, took place in eight hospital-based
antenatal centers in Scotland. A total of 250 women with type 1 diabetes
consented to participate in the study (a 94% participation rate of those
enrolled in and planning to deliver in the centers), and cord blood samples
were obtained from 200 subjects (80%). No differences in gestation at delivery,
maternal age at delivery, years of diabetes, fetal sex, or maternal A1C (where
available) were found between those with and without cord samples.
A detailed sampling protocol was placed in all centers with local training to
ensure standardization. Given the effects of delayed cord clamping on
stereological parameters (16) and to maximize cord blood available for
collection, on immediate delivery of the fetus, two disposable cord clamps
were placed at 10 cm from the umbilicus and a further two disposable cord
clamps were placed at 30 cm from the umbilicus. This allowed an isolated loop
of cord to be sampled for cord blood, facilitating the short median collection
time for cord samples and a constant volume of fetal blood in the placenta. On
delivery of the placenta, a ﬁfth clamp was placed at 1 cm from the chorionic
plate, with trimming of the cord to that level. To minimize effects of sample
hemolysis on insulin levels, samples were included only if collected from the
cord within 20 min and frozen within 60 min. The 200 samples were therefore
restricted to those in whom 1) there was no evidence of hemolysis of cord
blood (17 excluded); 2) cord blood had been collected within 20 min (12
exclusions: median [interquartile range] collection time for remaining samples
2 min [1–7]); 3) cord blood centrifuged and plasma frozen within 60 min (17
exclusions: time from collection to freezing for remaining samples, 17 min
[11–26]); 4) antenatal glucocorticoids not administered in the 24 h before birth
(15 excluded); 5) children delivered before 33 weeks’ gestation (5 excluded);
and ﬁnally 6) placental tissue sampled appropriately at time of birth (59
excluded). A total of 89 patients met these selection criteria.
A convenience sample of control mothers, with no history of obstetric or
metabolic disease and with negative routine screening for gestational diabetes
(national guidelines available at http://www.sign.ac.uk/guidelines/fulltext/55/
section8.html), were recruited from routine obstetric follow-up clinics after
the 34th week of pregnancy in the same centers at the same time. Of 145
women who gave initial consent, cord samples were attempted in 75 and
obtained in 70. Thirty-nine collections met the above restriction criteria.
Data on clinical outcome, including caesarean section, intercurrent medi-
cal conditions, and hypertensive conditions of pregnancy, were obtained by
case note review. Gestational ages were calculated from estimated dates of
delivery from chart review. This date was derived from dates of last menstrual
period (LMP), where available, or by ultrasound if there was either conﬂict
with dates as assessed by LMP (6 days) or LMP was unavailable.
Weight was measured at birth and, for offspring born between 33 and 42
weeks of gestation, further expressed as an SD score (17). Skinfold thickness
at subscapular and triceps was measured using Holtain calipers by pediatri-
cians at each site and using a centrally agreed protocol, which was
available in writing at the time of measurement. Skinfolds were not
measured in all subjects. There were no signiﬁcant differences in baseline
demographic or biochemical measures between those with and without
skinfold measurements in either control subjects or OT1DM (data not
shown). All mothers gave informed consent, and the local ethical commit-
tees approved protocols.
Stereological analysis. On completion of the cord-sampling procedure and
after delivery of the placenta, the placental membranes were trimmed, the
umbilical cord shortened to within 1 cm of the chorionic plate, and any large
maternal clots removed. Placentae were then weighed to the nearest 1 g. The
feto-placental index (birth weight [grams] divided by placental weight
[grams]) was calculated for each delivery. Samples of placenta were then
taken in a systematic random fashion. Speciﬁcally, the placenta was cut with
a sharp knife into a series of parallel slices 1–2 cm thick. The slices were then
diced into smaller blocks 2–3 cm wide and ﬁxed by immersion in 4%
formaldehyde for 24 h and subsequently embedded in parafﬁn wax. Placental
blocks were cut into 3-m sections and stained with hematoxylin and eosin.
These were used to estimate the volume fractions and surface areas as
previously described, with avoidance of section edges (10). Placentae from
OT1DM and control subjects were treated in an identical manner.
All estimates were made at the light microscope level by a combination of
point and intersect counting and computer-assisted length measurements
using the CAST system (version 2.0; Olympus, Glostrup, Denmark). Fields of
view were selected in a systematic random fashion and analyzed as previously
described (10) (Fig. 1). In brief, volume densities of intermediate and terminal
villi and of the villous trophoblast and capillaries were estimated by test point
counting. Villous and capillary surface densities were estimated by intersect
counting. For each placenta, 200 events were counted across 20 systematic
random ﬁelds of view per section. To convert volume and surface densities
into absolute values (in cm
3 and cm
2), the volume of each placenta was taken
as the reference volume. Volumes were calculated from trimmed placental
weights assuming a speciﬁc gravity of 1.05 g cm
3 (18,19). The intersections
of the test lines with the villous surface also provided random start points for
the measurement of orthogonal intercepts across the villous membrane, from
the microvilli to the nearest capillary lumen. Harmonic means of the intercept
lengths were calculated and then converted to diffusion distances. Given that
there are standard values for physiological constants of oxygen in red cells,
plasma, and tissues, including the villous membrane, the overall morphomet-
ric diffusing capacity for oxygen of the villous membrane of each placenta was
able to be derived from the formula described by Laga et al. (18). This is based
on the Fick equation and provides an estimate of the maximal theoretical
diffusion capacity of the placenta.
Changes of growth or adaptation of villi and the IVS were assessed by the
isomorphy coefﬁcient. Brieﬂy, this represents villous surface area, S, raised to
the power 3/2, and divided by the volume, V, of either the villous or intervillous
compartment (20) and is designed to measure disproportionate growth of
villous surface area compared with villous volume. Similarly, the coefﬁcients
for capillary surface area relative to villous and capillary volume were also
derived by S
3/2/V. The villous elaboration index, I  S/V
0.667, was also
calculated for each case. This index gives similar information to the villous
isomorphy coefﬁcient, with a high value representing increased elaboration of
the villous surface (8).
Cord blood assays. Plasma insulin, 32-33 split proinsulin, proinsulin, leptin,
IGF-I, adiponectin, plasma total cholesterol, triglycerides, nonesteriﬁed fatty
acid, VLDL cholesterol, LDL cholesterol, HDL cholesterol, C-reactive protein
(CRP), intercellular adhesion molecule (ICAM)-1, and interleukin (IL)-6 were
assayed as previously described (13,21–24). In particular, IGF-I was assayed
by chemiluminescence immunoassay (Nichols Institute Diagnostics, San Juan
Capistrano, CA) using standards referenced to the World Health Organization
1st International Reference Reagent 1988 (IGF-1 87/518). The limit of detec-
tion is 1.0 nmol/l. Intra- and interassay coefﬁcients of variation were 5.5–6.8%
and 5.4–7.0%, respectively. All lipid assays were carried out at the Biochem-
istry Department of Glasgow Royal Inﬁrmary, which is a Centers for Disease
Control and Prevention (Atlanta, GA) reference laboratory and accredited by
Clinical Pathology Accreditation U.K. Maternal A1C was measured centrally
by one laboratory.
Statistical analysis. Data were analyzed using standard software (Stata 10;
Stata, College Station, TX). In several cases (insulin, leptin, triglycerides,
VLDL, nonesteriﬁed fatty acids, total-to-HDL cholesterol ratio, CRP, ICAM-1,
FIG. 1. Stereological methodology. Randomly selected ﬁelds of view
were overlain with a quadratic test grid. Intersections between the test
lines acted as test points and were used for estimating the volume
fraction of the villous components by the point counting technique.
Intersections between the test lines and the villous (circles) or
capillary (squares) surfaces were counted to estimate the surface
densities. Intersections of the test lines with the villous surface also
acted as random start points for the estimation of villous membrane
thickness by measurement of orthogonal intercepts. (A high-quality
color digital representation of this ﬁgure is available in the online
issue.)
S.M. NELSON AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, NOVEMBER 2009 2635and IL-6), measures were not normally distributed, and unadjusted values are
presented as medians (interquartile range) and, for normally distributed
variables, means  SD. Variables were logarithmically transformed to obtain
normal distributions. Intergroup differences were assessed by unpaired t test
after checking homogeneity of variance by means of the F test, ANOVA, or,
where further predictor variables were included, by general linear models.
Exploration of more complex statistical models did not suggest alternative
relationships. Spearman correlation coefﬁcients are reported. Stepwise
logistic regression was performed using an  of P  0.1 for adding or
removing predictors from the model. Statistical signiﬁcance was deter-
mined at P  0.05.
RESULTS
Fetal cord analytes and placental structure in
OT1DM versus control subjects. Maternal and fetal
characteristics of this cohort have been previously de-
scribed and are included in Table 1. Maternal type 1
diabetes was associated with marked increases in stan-
dardized birth weight and absolute values of cord insulin,
proinsulin, and split 32-33 insulin (21); cortisol; leptin; and
CRP, with reductions in adiponectin, HDL cholesterol,
TABLE 1





Age (years) 28.4  6.0 30.0  5.0 0.13
Duration of diabetes (years) — 13.1  7.9
Parity
0 15 (38.5) 38 (43)
1 19 (49) 37 (42)
1 5 (12) 13 (15) 0.78
Maternal A1C (weeks)
5–12 — 7.8  1.2
16–24 — 6.8  0.9
26–34 — 7.0  1.0
35–40 — 6.7  1.0
Children (male/female) 19/20 42/46 0.92
Gestational age at delivery (weeks) 40.2  1.2 37.8  1.4 0.001
Mode of delivery
Vaginal 25 (64) 27 (31)
Elective caesarean section 8 (21) 35 (40)
Emergency caesarean section 6 (15) 26 (30) 0.002
Birth weight (kg)†
Male 3.77  0.52 3.81  0.72 0.05
Female 3.42  0.51 3.66  0.62 0.001
Z weight‡ 0.37  0.18 1.78  1.5 0.001
Placental weight (g) 641  22.3 690  19.0 0.08
Fetal-to-placental weight ratio 5.7  0.14 5.6  0.11 0.45
Cord indices
n 39 88
Cord insulin (pmol/l) 22.5 (16.6–39.6) 99.3 (57–219) 0.001
Proinsulin (pmol/l) 9.3 (6.6–12.6) 13.6 (9.9–22.2) 0.001
Split 32-33 insulin 10.6 (6.0–21.1) 43.8 (22.5–82.6) 0.001
Leptin (ng/ml) 9.1 (4.3–18.5) 29.5 (12.8–54.2) 0.001
IGF-I (mmol/l) 8.13  0.55 8.0  0.31 0.56
Adiponectin (g/ml) 22.2  5.2 20.0  6.4 0.068
Cortisol (nmol/l) 399.9 (264.3–531.7) 271.1 (195.8–395.0) 0.001
HDL cholesterol (mmol/l) 0.70  0.16 0.63  0.26 0.16
Triglycerides (mmol/l) 0.46 (0.38–0.58) 0.42 (0.33–0.55) 0.15
Nonesteriﬁed fatty acids (mmol/l) 0.25 (0.18–0.35) 0.17 (0.13–0.23) 0.001
CRP (mg/l) 0.14 (0.12–0.17) 0.17 (0.13–0.24) 0.002
ICAM-1 (ng/ml) 165.6 (143.0–188.2) 179.7 (152.6–201.1) 0.07
IL-6 (pg/ml) 7.35 (2.4–12.4) 4.0 (2.4–9.3) 0.03
Hematocrit (%) 0.51 (0.48–0.54) 0.54 (0.49–0.58) 0.08
Platelets (10
9/l) 245 (113–300) 229 (185–262) 0.42
Offspring anthropometry
n 17 40
Crown rump length (cm) 33.7  2.4 34.9  2.3 0.079
Crown heel length (cm) 50.3  3.0 50.9  2.4 0.43
Triceps skinfold thickness (mm) 5.85  2.4 7.66  3.2 0.04
Subscapular skinfold thickness (mm) 5.53  2.1 7.44  2.2 0.004
Total skinfold thickness (mm) 11.38  4.2 15.10  5.0 0.01
Data are means  SD, n (%), or medians (interquartile range). Unadjusted values are given as means  SD or medians (interquartile range).
*P  value of signiﬁcance in unpaired t, 	
2, or Mann-Whitney test, as appropriate. †Birth weights given as unadjusted P value for difference
dependent on maternal diabetes status adjusted for gestational age at delivery. ‡Z weight is SD score compared with standard values for
gestational age, sex, and maternal parity. A subset of offspring had detailed anthropometry performed. Cord hormonal proﬁles of singleton
OT1DM vs. control offspring are shown.
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remained signiﬁcant after adjustment for sex and mode of
delivery. There was a trend toward increased placental
weight in OT1DM strengthened by adjustment for sex and
gestation at delivery (P  0.06). Feto-placental index did
not differ (Table 1).
Analysis of placental stereological data demonstrated
that intervillous space volume fraction and absolute inter-
villous space volume were increased in OT1DM (Table 2).
Adjustment for mode of delivery, sex, gestational age at
birth, and smoking status strengthened this difference for
both (P  0.028 and P  0.008, respectively). The contri-
bution of trophoblast to villous structure was reduced in
OT1DM (P  0.01); however, this was not associated with
an overall reduction in trophoblast volume or villous
surface area (Table 2). Absolute values of capillary volume
and surface area were similarly unaltered by the presence
of maternal diabetes.
Assessment of the complexity of the villous trees using
the villous isomorphy coefﬁcient and the elaboration index
demonstrated that branching was reduced in OT1DM (P 
0.025 and P  0.019, respectively). With respect to capil-
lary development, the ratio of capillary surface area rela-
tive to capillary volume was also reduced in OT1DM (P 
0.01). The villous isomorphy coefﬁcient and elaboration
index were unrelated to gestational age, mode of delivery,
sex, and smoking status. Capillary development, as related
to capillary surface area relative to capillary volume,
however, was related to gestational age and adjustment
attenuated the OT1DM-speciﬁc difference (P  0.24).
Placental composition, relationship with birth weight,
and adiposity. Assessment of the relationship of birth
weight to placental structure demonstrated a strong asso-
ciation with placental weight (control subjects, r  0.62,
P  0.0001; OT1DM, r  0.62, P  0.0001), with additional
strong correlations of birth weight to the individual pla-
cental components, including villous volume (control sub-
jects, r  0.34, P  0.03; OT1DM, r  0.24, P  0.03),
intervillous space volume (control subjects, r  0.58, P 
0.001; OT1DM, r  0.44, P  0.0001), and nonparenchymal
volume (control subjects, r  0.24, P  0.13; OT1DM, r 
0.42, P  0.0001) in control subjects and OT1DM. All
relationships were strengthened after standardizing birth
weight for gestational age and sex (P  0.05 for controls
and OT1DM for all). Capillary volume (r  0.23, P  0.03)
and capillary surface area (r  0.21, P  0.05) were
associated with standardized birth weight in OT1DM only.
For the subset with neonatal anthropometry, total skinfold
thickness was associated with placental weight (control
subjects, r  0.36, P  0.15; OT1DM, r  0.31, P  0.05)
and capillary volume (control subjects, r  0.13, P  0.62;
OT1DM, r  0.32, P  0.046), with no relationship seen
with other placental components.
Placental composition and relationship with fetal
hormones. Analysis of the associations of fetal hormonal
axes to placental compartments demonstrated that insu-
lin, in addition to known associations with birth weight
(r  0.42, P  0.0001) and placental weight (r  0.44, P 
0.0001) in OT1DM, demonstrated OT1DM-speciﬁc correla-
tions to villous volume (r  0.23, P  0.03), intervillous
space volume (r  0.25, P  0.02), nonparenchymal
volume (r  0.23, P  0.03), and capillary volume (r 
0.27, P  0.009). Cord IGF-I levels were associated with
birth weight in control subjects and OT1DM (control
subjects, r  0.32, P  0.04; OT1DM, r  0.48, P  0.0001)
but only correlated with placental weight and substruc-
TABLE 2
Placental stereology of mothers with type 1 diabetes versus control mothers
Control mothers
Mothers with
type 1 diabetes P*
n 39 88
Volume fractions
Intervillous space volume fraction (cm
2 
 cm
3) 0.4  0.1 0.4  0.10 0.06
Villous volume fraction (cm
2 
 cm
3) 0.4  0.1 0.4  0.1 0.83
Nonparenchymal volume fraction (cm
2 
 cm
3) 0.2  0.1 0.2  0.1 0.58
Trophoblast volume fraction (cm
2 
 cm
3) 0.2  0.0 0.2  0.0 0.01
Capillary volume fraction (cm
2 
 cm
3) 0.1  0.0 0.1  0.0 0.28
Compartment volumes
Intervillous space volume (cm
3) 216.7  65.2 250.3  81.2 0.02
Villous volume (intermediate  terminal villi) (cm
3) 217  70.3 231.6  95.8 0.39
Nonparenchymal (stroma  ﬁbrin) (cm
3) 130.2  59.6 131.9  65.1 0.90
Trophoblast volume (cm
3) 49.7  20.0 48.1  23.3 0.72
Capillary volume (cm
3) 24.3  16.2 27.9  19.9 0.32
Surface areas
Villous surface area (m
2) 4.0  7.2 12.7  6.8 0.34
Capillary surface area (m
2) 14.4  9.1 13.7  9.7 0.73
Villous membrane thickness (m) 9.3  1.2 9.2  1.0 0.59
Morphometric diffusing capacity (cm
2  min
1  kPa
1) 2.7  1.6 2.5  1.6 0.50









3) 239,317  125,212 192,225  99,827 0.025
Intervillous space coefﬁcient (cm
3/cm
3) 275,676  215,189 220,532  192,795 0.154
Capillary surface area relative to villous volume 250,770  172,032 219,690  177,986 0.36
Capillary surface area relative to capillary volume 2,338,266  1,033,081 1,854,403  921,906 0.010
Capillary volume relative to villous volume 0.1  0.04 0.1  0.0 0.28
Villous elaboration index 3,759  1,212 3,226  1,138 0.019
Data are means  SD. *P  value of signiﬁcance in unpaired t test.
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0.49, P  0.0001), villous volume (r  0.23, P  0.03),
intervillous space volume (r  0.35, P  0.001), and
nonparenchymal volume (r  0.29, P  0.005), with a
weaker relationship to capillary volume (r  0.18, P 
0.08). Cord leptin values demonstrated associations with
birth weight (control subjects, r  0.48, P  0.002;
OT1DM, r  0.40, P  0.0001) and placental weight
(control subjects, r  0.40, P  0.01; OT1DM, r  0.33, P 
0.0019) in control subjects and OT1DM but were only
related to intervillous space volume (control subjects, r 
0.30, P  0.07; OT1DM, r  0.32, P  0.002). Assessment
of maternal glycemic state in OT1DM demonstrated that
maternal A1C at 26–34 weeks was associated with birth
weight (r  0.27, P  0.03), placental weight (r  0.41, P 
0.0009), intervillous volume (r  0.38, P  0.0024), and
nonparenchymal volume (r  0.25, P  0.05). First- and
third-trimester maternal A1C demonstrated similar relation-
ships with intervillous volume (r  0.34, P  0.059; r 
0.31, P  0.03, respectively) but not with any of the other
placental parameters including placental weight. Cord
adiponectin and cortisol were unrelated to birth weight or
placental parameters, and no consistent associations were
observed for fetal inﬂammatory indexes, fetal hematocrit
or fetal lipids, and placental composition. Isomorphy
coefﬁcients were also unrelated to birth weight, placental
weight, or cord analytes in control subjects or OT1DM.
In stepwise regression models (Table 3), cord IGF-I was
associated with intervillous volume in control subjects and
OT1DM, with further contributions of IGF-I to nonparen-
chymal volume, trophoblast volume, capillary volume,
villous surface area, and theoretical diffusion capacity in
OT1DM (P  0.05 for all). In contrast, insulin was only
positively associated with capillary surface area, an asso-
ciation that was restricted to OT1DM (P  0.017). Inclu-
sion of maternal A1C at 26–34 weeks attenuated this
association with insulin, and IGF-I became the sole asso-
ciate of capillary surface area (0.87  0.4, P  0.022,
r
2  8.9%). Notably, A1C at 26–34 weeks was not related
to any other placental parameters and did not alter the
noted associations of IGF-I demonstrated in Table 3 and
indeed made IGF-I the sole associate of nonparenchymal
volume in OT1DM (5.2  2.7, P  0.06, r
2  6.1%). For
the isomorphic variables, insulin was associated with
capillary surface area relative to both villous volume and
capillary volume (Table 3), an effect that was partially
explained by maternal A1C.
To assess the role of fetal hypoxia in determining
placental structure, the surrogate marker of fetal hemato-
crit was included in the models. This did not attenuate the
associations of IGF-I with placental structure in OT1DM.
However, in control subjects, fetal hematocrit demon-
strated positive associations with intervillous volume (P 
0.023), which was independent of sex (P  0.06), and
leptin (P  0.036), with IGF-I dropping out of the model.
Fetal hematocrit was also associated in control subjects
with capillary volume (P  0.043), which was independent
TABLE 3
Multivariate analysis of independent correlates of placental structure in OT1DM and control subjects
Control mothers Mothers with type 1 diabetes
Associate SE P
Variance




volume IGF-I 5.8  3.3 0.09 8.4 IGF-I 9.8  2.8 0.001 22.6
Leptin 35.7  15.3 0.022
Adiponectin 2.2  1.3 0.081
Villous volume — — — — IGF-I 14.4  3.3 0.001 18.6
Nonparenchymal
(stroma  ﬁbrin) — — — — Mode of
delivery
14.7  5.5 0.009 7.9
Trophoblast volume Mode of
delivery
5.1  2.5 0.05 18.4 IGF-I 2.5  0.8 0.005 9.3
Adiponectin 1.1  0.6 0.10
Capillary volume Leptin 10.7  6.3 0.10 7.8 IGF-I 2.1  0.7 0.005 9.0
Villous surface area — — — — IGF-I 0.6  0.3 0.021 6.3




0.3  0.2 0.06 10.0 — — — —
Theoretical diffusing
capacity — — — — IGF-I 0.15  0.06 0.012 7.4
Capillary surface area
relative to villous





161,606  87,257 0.068
Insulin 560,045  238,033 0.021
Leptin 334,678  200,058 0.098 8.1
Stepwise regression with log(insulin), log(leptin), adiponectin, IGF-I, mode of delivery, and sex was performed with an  of P  0.1 for adding
or removing predictors from the model. Variance (%) explained by the model.
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0.013) (Table 3).
DISCUSSION
To our knowledge, this is the largest series examining
placental stereology in a contemporary cohort of women
with type 1 diabetes. It gives an important opportunity
both to examine the inﬂuence of maternal diabetes on
placental structure and to assess whether hormones in the
fetal circulation (particularly insulin and leptin, which are
markedly raised in this cohort) correlate with placental
substructure. We ﬁnd that, overall, there are relatively few
systematic differences between placentas from mothers
with diabetes and control subjects. In particular, the key
measures that might be expected to inﬂuence substrate
diffusion across the placenta (villous surface area, capil-
lary surface area, villous membrane thickness) are not
altered. In keeping with this, the placental morphometric
diffusing capacity was also not different between diabetic
and control pregnancies.
Historically, a range of abnormalities have been de-
scribed in the placenta in type 1 diabetes, including
increased placental size in conjunction with fetal macro-
somia. In the oldest series, gross pathology including an
increased rate of placental infarcts was described, as well
as villous immaturity. In the series from the 1990s, micro-
scopic morphology was often described as normal, partic-
ularly where maternal diabetes was well controlled (25).
Increases in capillary volume and surface area (6,7),
villous surface area (8), increased total diffusive conduc-
tance (9), and intervillous and trophoblast volume (7,10)
were described and their presence or absence often as-
cribed to the degree of maternal diabetes control. In our
series, we did not observe these changes with the excep-
tion of an increase in intervillous space volume, which
classically indicates a deﬁciency of terminal villi and
persisting villous immaturity. Consistent with this and
previous reports (20), we observe a reduction in the
villous coefﬁcient and elaboration index, measures of the
complexity of the villous tree that would impinge upon the
intervillous space, suggesting that the observed villous
growth is anisomorphic. Importantly, however, despite
this reduction in villous development, there is no overall
impact on villous volume or surface area, primarily due to
an increased total placental volume in OT1DM. One might
speculate that the reduction in villous development and
increased placental growth are compensatory changes,
but it is not possible to determine the primary direction of
this relationship. Appropriately, we demonstrate that indi-
vidual placental components, including villous volume, all
correlate with birth weight.
Despite these limited changes, the inconsistent nature
of the studies to date, combined with the major ﬁndings of
our series, supports the view that there are minimal
changes in placental structure inherent in contemporary
diabetic pregnancy. This is of interest, as the overall
hormonal environment on the fetal side of the circulation
is markedly abnormal, with median fetal insulin and leptin
levels four and three times higher, respectively, than
control subjects. It is therefore striking that these signiﬁ-
cant increases in insulin and leptin do not appear to be
driving any consistent change in placental structure. Only
IGF-I displayed a consistent relationship with the volumes
of the intervillous space, villous trophoblast, and placental
capillaries.
Insulin has classically been proposed as a mediator of
enhanced placental development in type 1 diabetes and
was thought to underlie the reported increases in prolif-
eration rates of trophoblast, villous stromal cells, and
villous capillaries. However, insulin is not usually trans-
ported across the villous membrane, and its effects may be
different on the fetal and maternal side of the placenta. In
the ﬁrst trimester, insulin receptors are localized to the
intervillous surface of the villous trophoblast, with expres-
sion predominantly on the surfaces of sprouting segments
of the villous tree (26). In contrast, by the third trimester,
the highest immunoreactivity for the insulin receptor is
found in the fetal villous endothelium, in particular, in
segments with capillary sprouting (27). Further analysis of
the transcriptional proﬁle and phosphorylation status of
ﬁrst- and third-trimester isolated trophoblast and endothe-
lial cells in response to hyperinsulinemia suggests that
there is a spatio-temporal shift in insulin response (28),
leading to the hypothesis that there is a predominant effect
of maternal insulin in early pregnancy and fetal insulin in
later pregnancy (27). Fetal insulin levels would be pre-
dicted to contribute to control of villous differentiation in
accordance with fetal growth and nutritional needs in later
pregnancy. In the current study, we demonstrate that fetal
insulin is an independent associate of capillary surface
area and of capillary surface area relative to villous and
capillary volume. Our observed relationship with capillary
development would be consistent with insulin receptor
localization to endothelial cells and the ability of fetal
insulin to enhance capillary development, including longi-
tudinal growth within a ﬁxed villous volume (6). It is
notable, however, that there appears to be little impact of
fetal insulin on trophoblast volumes independent of the
effects of IGF-I. In this analysis, we rely on cord measures
of insulin and IGF-1. It is possible that fetal hyperinsulin-
emia earlier in pregnancy is acting; however, if hyperinsu-
linemia is established earlier in pregnancy, it is likely that
cord insulin will also be increased. This is apparent in the
strong relationship of cord insulin and IGF-1 to measures
such as birth weight (13) and our biologically plausible
association of fetal insulin with placental capillary
volumes.
The relationship of circulating fetal IGF-I to many of the
placental components is striking. Cord IGF-I is strongly
associated with birth weight and placental weight (12),
and IGF-I deletion or reduced receptor expression in
humans are both associated with a reduction in birth
weight and placental weight (29,30). Conversely, pro-
longed administration of exogenous IGF-I to growth-re-
stricted fetuses substantially increases body and placental
weight (31). In short-term studies, exogenous fetal IGF-I
increases placental amino acid transfer and uptake and
decreases proteolysis, facilitating organ-speciﬁc and pla-
cental growth (32). These relationships are in contrast to
those observed in mice, suggesting species speciﬁcity,
where deletion of IGF-I or its receptor IGF-Ir is associated
with a signiﬁcant reduction in fetal but not placental
weight (33). Therefore, although IGF-I may directly be
enhancing placental growth, via receptors expressed in
trophoblast and endothelium (34–36), alternative indirect
mediators like adiponectin, which have been implicated in
the matching of fetal and placental weight, may contribute
(11,14). However, cord levels of IGF-I and adiponectin are
not correlated, and adiponectin was not an independent
associate in the multivariate models. Fetal lipids, in par-
ticular HDL, is associated with IGF-1 in fetal and adult life
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of fetal lipids with placental parameters (data not shown)
despite recent recognition that placental endothelial cells
efﬁciently transport cholesterol (39). Similarly, although
inﬂammatory signals, including IL-6, can increase IGF-I
expression (40), we did not observe an independent effect
of inﬂammatory mediators on placental parameters (data
not shown). Lastly, inclusion of fetal hematocrit, an index
of fetal hypoxia, did not alter these relationships but did
demonstrate the expected positive association with capil-
lary volume in multivariate models. Overall, our results
would support the hypothesis that, in humans, IGF-I has a
direct effect on placental development.
Leptin has also been proposed as a regulator of placen-
tal growth. In human trophoblast cells in vitro, exogenous
leptin treatment has mitogenic and antiapoptotic effects,
while inhibition of endogenous placental leptin expression
reduces cell proliferation and increases apoptotic cell
number and caspase-3 activity (41). Furthermore, leptin
stimulates activity of the amino acid transporter system A
in human placental villous fragments at term (42,43).
Lastly, leptin can induce angiogenesis in primary cultures
of endothelial cells (44). Despite these effects, leptin
infusion does not induce signiﬁcant placental growth in
sheep (45), and in the current study, leptin did not show
consistent relationships with placental components in the
control subjects. This limited effect may reﬂect differential
leptin receptor expression, as although leptin receptors
have been localized to umbilical endothelial cells and
trophoblast (46,47), they have not been demonstrated on
placental endothelium, which may explain our observed
lack of association of fetal leptin with stereological param-
eters. Although leptin exerted a small inﬂuence on inter-
villous space volume independent of IGF-I in the OT1DM
placentas, leptin is markedly raised in OT1DM, suggesting
that the ability of leptin to induce placental angiogenesis
and growth may be limited.
Maternal A1C is associated with both birth weight and
placental weight in this series. It is notable, however, that
maternal diabetes and indeed maternal A1C are not related
to most of the placental stereological parameters with the
exception of intervillous space volume. This would sug-
gest that excess maternal nutrient supply may not be
primarily responsible for changes in placental develop-
ment, and, where present, such changes and increases in
placental weight in general follow increased fetal weight.
A notable feature of this study is the close matching of
fetal growth with placental size, including placental com-
ponents. It would appear that the fetus is capable of
modulating placental transport in response to metabolic
demands and nutrient supply. The signals that facilitate
this feedback loop are largely unknown; however, this
study suggests that IGF-I, and to a lesser extent insulin and
leptin, all contribute and facilitate varying degrees of
morphological alternation.
In conclusion, we demonstrate that maternal type 1
diabetes is associated with minimal changes in placental
structure and that the changes that do occur relate prin-
cipally to villous maturity. Second, we identify that fetal
IGF-1 is the principal correlate of placental substructure
and that the effect of insulin is limited to capillary devel-
opment. Lastly, we identify that fetal leptin has a limited
positive effect on placental angiogenesis and, in conjunc-
tion with IGF-I and insulin, contributes to the metabolic
feedback from the fetus to the placenta regarding its
metabolic demands.
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